Adagene Inc.
NASDAQ:ADAGBiotechnology
+$0.13 today
- Market cap
- $68.52M
- Beta
- 0.59
- P/E (TTM)
- -7.9
- EPS (TTM)
- -$0.47
Volume 1.30M
Average 0.21M
ADAG Total Current Liabilities
All obligations due within one year.
Adagene Inc.NASDAQ: ADAG
Total Current Liabilities · Q4 FY2025 · quarter ended Dec 2025
Total current liabilities falls 34.1% from a year ago
Total current liabilities stood at $25.17M at the end of Q4 FY2025, down 34.1% from a year earlier. Over 3 fiscal years it compounded at -23.0% a year.
Context
- Total current liabilities amounted to 32.2% of total assets at the end of Q4 FY2025, down 10.6 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -34.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 25.17M USD
- Year-over-year change
- -34.1%
- 4-year CAGR
- -4.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.17M | -34.1% |
| FY2024 | 2024-12-31 | 38.18M | +21.4% |
| FY2023 | 2023-12-31 | 31.46M | -42.9% |
| FY2022 | 2022-12-31 | 55.08M | +84.7% |
| FY2021 | 2021-12-31 | 29.82M | — |
Total Current Liabilities vs competitors
How ADAG compares with its peers on the latest reported figures
- ADAG's Dec 2025 total current liabilities of $25.17M is the 3rd highest of the 9 companies compared; the peer median is $17.63M.
- Its year-over-year change of -34.1% is the 8th highest of 9, against a peer median of -16.4%.
- Total current liabilities amounts to 32.2% of total assets for ADAG, versus a peer median of 16.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $103.39M | +40.3% | -27.0% | 29.0% | |
| Mar 2026 | $25.18M | -23.1% | +22.4% | 211.5% | |
| Dec 2025 | $25.17M | -34.1% | -23.0% | 32.2% | |
| Mar 2026 | $19.97M | -33.0% | +2.6% | 9.9% | |
| Mar 2026 | $18.3M | +11.3% | +3.0% | 10.8% | |
OSTXOS Therapies Incorporated | Mar 2026 | $16.95M | +379.4% | +24.2% | 232.3% |
| Mar 2026 | $3.89M | -22.7% | -6.7% | 20.7% | |
| Mar 2026 | $3M | -44.6% | +24.9% | 2.1% | |
| Apr 2026 | $832.14K | -10.0% | +1.6% | 12.1% | |
| Peer median (excluding ADAG) | $17.63M | -16.4% | +2.8% | 16.4% | |
Competitors are the stored peer set for ADAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 174.39M | 143.76M | 109.93M | 85.19M | 74.52M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 7.51M | 619.43K | 222.03K | 8.31K | 17.35K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.49M | 3.78M | 2.7M | 527.71K | 1.2M |
| Total Current Assets | 185.95M | 149.32M | 113.44M | 87.78M | 77.38M |
| Property, Plant & Equipment (Net) | 3.49M | 2.97M | 2.2M | 1.41M | 862.91K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 69.28K | 109.57K | 84.89K | 103.5K | 25.22K |
| Total Non-current Assets | 3.56M | 3.08M | 2.29M | 1.51M | 888.13K |
| Total Assets | 189.51M | 152.4M | 115.73M | 89.27M | 78.26M |
| Account Payables | 3.32M | 3.67M | 3.09M | 4.24M | 2.88M |
| Short-term Debt | 4.5M | 13.62M | 8.4M | 17.79M | 4.98M |
| Tax Payables | 1.66M | 349.04K | 52.88K | 485.97K | 998.51K |
| Deferred Revenue | 5.5M | 15.11M | 0 | 0 | 3.46M |
| Other Current Liabilities | 11.62M | 111.92K | 119.75K | 56.27K | 232.24K |
| Total Current Liabilities | 29.82M | 55.08M | 31.46M | 38.18M | 25.17M |
| Long-term Debt | 2.99M | 14.15M | 13.54M | 417.34K | 1.14M |
| Deferred Tax Liabilities | 44.16K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 94.11K | 28.72K | 0 | 0 | 16.55M |
| Total Non-current Liabilities | 3.13M | 14.23M | 13.71M | 559.64K | 17.74M |
| Total Liabilities | 32.95M | 69.31M | 45.17M | 38.74M | 42.91M |
| Common Stock | 5.63K | 5.5K | 5.55K | 5.89K | 5.92K |
| Retained Earnings | (178.83M) | (258.81M) | (277.75M) | (311.18M) | (328.79M) |
| Accumulated OCI | (93.98K) | (849.31K) | (1.8M) | (526.9K) | (1.91M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 156.56M | 83.09M | 70.56M | 50.52M | 35.35M |
| Total Debt | 7.49M | 27.97M | 22.31M | 18.49M | 6.26M |
| Net Debt | (166.9M) | (115.79M) | (87.63M) | (66.7M) | (68.26M) |
Adagene Inc.
NASDAQ:ADAG
Intrinsic Alpha fair value
Locked
Current Price
$1.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.